Antiglutamate Anticonvulsants in the Treatment of Alcohol Withdrawal Syndrome

The study is aimed to evaluate the efficacy of antiglutamate anticonvulsants (topiramate, lamotrigine, and memantine) in the treatment of alcohol withdrawal syndrome

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Topiramate Diazepam Lamotrigine Memnatine Placebo

Age range

20 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Alcohol dependence Alcohol withdrawal syndrome

Exclusion criteria

Drug dependence Major psychiatric diagnoses Severe somatic illness

Treatment and study plan

Anticonvulsants

Drug

Sponsors and collaborators

Lead sponsor

St. Petersburg State Pavlov Medical University

Other

Registry information

Important dates

First posted: Oct 19, 2005
Registry last updated: Oct 18, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed